|
| |
| |
 |
Research |
|
|
| |
Research AUB
The
Program was awarded the Outstanding
Clinical Program Departmental Award on
June 12, 2004. The selection was driven
by the very high productivity of the
program in research, attracting a high
level of funding institutionally and its
success in achieving visibility not only
nationally and regionally, but also
internationally. The Program’s
publications over the last five years
have achieved the highest cumulative
impact factor institutionally.
Manuscript describing various
studies/reviews from the Program are
published in the N Engl J Med, J Bone
Miner Res, J Clin Endocrinol Metab,
Bone, Am J Clin Nutr, amongst others.
Research Program
Revolves around the evaluation of the
epidemiology of osteoporosis in Lebanon,
prevention and treatment of osteoporosis
and evaluation and treatment of
secondary causes of bone loss.
-
Osteoporosis
- Epidemiology of osteoporosis in
Lebanon
- Pathophysiology, prevention and
therapies of osteoporosis
- Hypovitaminosis D in Lebanon:
risk factors and skeletal
implications
- Nutrition as a risk factor for
osteoporosis in Lebanon
- Skeletal health in children and
its determinants
- Genetic programming
- Heritability of bone density
- Hip fracture and its
determinants
- Bone density / fracture
relationship in the Lebanese and
the Middle East
-
Hypovitaminosis D and
impact on musculoskeletal health
across the lifecycle
- Materno-neonatal: fetal
programming
- Childhood and adolescents
- Elderly
-
Women’s Health
- Education
- Women’s attitudes in Lebanon
regarding women’s health
- Strategies to improve compliance
with osteoporosis prevention
strategies
-
Applications of Bone
Densitometry Measurements
- Fracture risk assessment models
- Physician performance in BMD
reporting
-
Secondary Causes of
Bone Loss
- Effect of anticonvulsants on
mineral and skeletal metabolism
- Osteoporosis in renal failure
- Transplantation bone disease
- Effect of pulse steroid therapy
and inhalational steroids on
bone metabolism
- Chemotherapy-induced bone loss
- Effect of topical steroids on
bone metabolism
-
Hyperparathyroidism
and Abnormal PTH Dynamics
- Classical and non classical
manifestations in Lebanon
- Bone disease in
hyperparathyroidism
- Familial HPTH: study of a Syrian
family with the jaw tumor
syndrome
- Familial benign hypocalciuric
hypercalcemia
-
Multicenter Trials
-
2003-2006
Ghada
El-Hajj Fuleihan, MD, MPH.
Principle Investigator.
Co-investigators: Asma Arabi,
Joyce Maalouf.
A randomized, double blind,
placebo-controlled, parallel
group, multicenter, two years
phase III study to determine the
efficacy and safety of
Risedronate therapy administered
35 mg once a week in Men with
osteoporosis. MASTER trial
Aventis/ Procter and Gamble.
-
2005-2007
Ghada
El-Hajj Fuleihan, MD, MPH.
Principle Investigator.
Co-investigators: Asma Arabi,
Joyce Maalouf.
A multicenter, double –blind,
randomized, active controlled,
parallel group, non-inferiority
study comparing 75 mg
risedronate dosed on two
consecutive days monthly with 5
mg daily risedronate in the
treatment of postmenopausal
osteoporosis as assessed over 24
months. Aventis
-
2008-2010
Ghada El-Hajj
Fuleihan, MD, MPH. Principle
Investigator.
Co-investigators: Miguel Abboud, Samar Muwakkit, Asma Arabi, Lina
El-Onsi
"A randomized , open-label
efficacy and safety trial of
intravenous zoledronic acid with
vitamin D and calcium versus
vitamin D and calcium alone in
childhood cancer survivors with
low bone mass".
-
2011-2015
Ghada El-Hajj Fuleihan, MD, MPH.
Principle Investigator.
Co-investigators:
AUB:
Asma Arabi, Robert Habib
HDDF:
Rafic Baddoura and Georges
Halabi
RHUH:
Samer Kabbani, Wissam Nasreddine,
Mohammad Rawwas
“Hypovitaminosis D: A Link
between Bone and Fat Fuel
Metabolism”. Funded by AUB, SJU
and LCNRS
|
|
|
|
